Reuters: Regulatory News: EU regulators charge J&J, Novartis over Dutch painkiller delay

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

EU regulators charge J&J, Novartis over Dutch painkiller delay Jan 31st 2013, 10:47 BRUSSELS | Thu Jan 31, 2013 5:47am EST BRUSSELS Jan 31 (Reuters) - EU antitrust regulators charged pharmaceutical firms Johnson & Johnson and Novartis on Thursday over the delay of a generic competitor for painkiller fentanyl in the Dutch market. The European Commission, which acts as antitrust regulator in the 27-nation European Union, said it had sent a "statement of objections" or charge sheet to the companies over an agreement between their Dutch subsidiaries. "If our preliminary conclusions are confirmed, the Dutch subsidiaries of Johnson & Johnson and Novartis entered into a so-called 'co-promotion' agreement to avoid competing against each other, depriving users of fentanyl in the Netherlands from access to a cheaper painkiller," the Commission said in a statement. The charges arose from an investigation of the pharmaceuticals sector after a Commission report highlighted deals between major drugmakers aimed at hindering or blocking generic medicines in "pay-for-delay" deals.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions